“Including dietary supplements in clinical recommendations will expand the consumer base and strengthen public trust. However, there is a risk of excessive regulation. The requirement to reference active ingredients in dietary supplements solely within Russian clinical guidelines appears overly stringent, given the lack of consensus on the efficacy of many nutraceuticals. This may result in the withdrawal of beneficial products from the market. Assessing dietary supplements according to criteria applicable to medicinal products distorts the nature of the category and hampers innovation. What is needed is flexible regulation that encourages product diversity and meets consumers’ healthcare needs.”